Aarhus N

• Effects of empagliflozin on plasma glucose in patients with HNF1A-MODY: a randomized, double-blind, crossover trial Ended
  2023-503760-17-00 4 2023-10-11 Maturity-onset diabetes of the young type 3 (HNF1A-MODY)
• Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors Ended
  2022-502787-20-00 4 2023-09-28 Melanoma and squamous cell carcinoma of the head and neck
• Treatment of Chronic Hand Eczema with Oral Roflumilast (HERO) Ended
  2022-503011-42-00 4 2023-09-25 Chronic hand eczema
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• Clonidine for postoperative pain management in patients undergoing spine surgery Ended
  2023-505969-80-00 4 2023-09-05 Degenerative spine diseases
• A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and … Ended
  2022-502382-25-00 4 2023-08-24 Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WH
• A Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) in Subjects with Fuchs Dystrophy Ended
  2022-502643-35-00 5 2023-08-09 Fuchs Endothelial Corneal Dystrophy
• The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the tr … Ended
  2022-500449-26-00 6 2023-08-03 Type 2 diabetes mellitus (T2DM)
• Safety and efficacy of NMD670 in ambulatory adult patients with Type 3 spinal muscular atrophy (SYNAPSE-SMA) Ended
  2024-516321-31-00 4 2023-07-07 Type 3 spinal muscular atrophy
• Adipose-derived mesenchymal stem cells as local treatment of ulcerative colitis Ended
  2024-518643-38-00 9 2023-06-30 ulcerative colitis
• Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Ended
  2024-512554-15-00 5 2023-06-21 COVID-19
• A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype … Ended
  2022-503022-13-00 5 2023-06-08 Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501753-36-00 5 2023-06-02 Hidradenitis Suppurativa
• Plethysmography with acetylcholin and carbacholin – A clinical method study Ended
  2023-503908-87-00 4 2023-06-02 Vascular dysfunction
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th … Ended
  2022-500121-33-01 5 2023-05-08 Anti-GBM antibody disease (Goodpasture disease)
• A Study to Investigate the Safety and Effectiveness of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial … Ended
  2024-511752-40-00 5 2023-05-05 Fuchs Endothelial Corneal Dystrophy
• Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Ped … Ended
  2023-507144-36-00 5 2023-04-20 Juvenile psoriatic arthritis
• A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended
  2023-506352-24-00 5 2023-04-13 Non-obstructive Hypertrophic Cardiomyopathy
• Thiamine Against Chronic Rheumatoid Arthritis Fatigue Ended
  2022-500922-13-00 10 2023-02-16 Rheumatoid Arthritis
• A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Ended
  2024-514761-19-00 5 2023-01-25 Idiopathic Pulmonary Fibrosis
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• Treatment with Xeljanz in a population of patients with cutaneous T cell lymphoma Ended
  2022-500599-79-00 4 2023-01-10 Mycosis Fungoides
• A Phase IIa Study to assess Safety, Tolerability, and Pharmacodynamics of AZD4831 in Adult Participants with Non-cirrhotic NASH with Fibrosi … Ended
  2022-500594-13-00 4 2022-12-14 "Non-Alcoholic Steatohepatatis (NASH) is the progressive form of Non-A
• Insulin Resistance and Statin Treatment in Renal Transplant Recipients and Patients with Chronic Kidney Disease Ended
  2022-501068-16-00 4 2022-12-14 Insulin resistance

Showing 505–528 of 582 trials